- Merck (NYSE:MRK +2.1%) net profit $781M vs $908M a year earlier,
- Earnings were hurt by patent expirations and currency fluctuations.
- Sales breakdown: Pharmaceuticals flat at $9.76B, with Januvia +4%, Zetia +9%, Remicade +9%, Janumet +11%, Gardasil -9%; Animal Health -1%, consumer care +1%.
- Guidance: 2014 adjusted EPS of $3.35-3.53 vs consensus of $3.48; revenues $42.4-43.2B vs $43.35B. (PR)
- Previous
More on Merck Q4: Net profit falls to $781M
Recommended For You
More Trending News
About MRK Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
MRK | - | - |
Merck & Co., Inc. |